Barclays PLC Acquires 641,646 Shares of Evolent Health, Inc. (NYSE:EVH)

Barclays PLC grew its position in Evolent Health, Inc. (NYSE:EVH - Free Report) by 234.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 915,422 shares of the technology company's stock after acquiring an additional 641,646 shares during the quarter. Barclays PLC owned approximately 0.79% of Evolent Health worth $10,298,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Pilgrim Partners Asia Pte Ltd bought a new position in Evolent Health during the 4th quarter worth $26,000. R Squared Ltd bought a new position in Evolent Health during the 4th quarter worth $31,000. AlphaQuest LLC grew its stake in Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock worth $34,000 after buying an additional 3,031 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after buying an additional 2,358 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in Evolent Health during the 4th quarter worth $61,000.

Evolent Health Price Performance

NYSE:EVH traded up $0.33 during mid-day trading on Monday, reaching $9.31. 2,812,721 shares of the stock were exchanged, compared to its average volume of 2,351,884. The business has a fifty day moving average price of $9.51 and a 200 day moving average price of $12.37. The firm has a market capitalization of $1.09 billion, a PE ratio of -11.35 and a beta of 1.20. Evolent Health, Inc. has a 1-year low of $8.35 and a 1-year high of $33.63. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. The firm had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Research analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Piper Sandler restated an "overweight" rating and set a $16.00 price objective (down from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Oppenheimer lowered their price objective on Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday, January 24th. JMP Securities reissued a "market outperform" rating and issued a $13.00 price target on shares of Evolent Health in a research note on Monday. Needham & Company LLC reissued a "buy" rating and set a $15.00 price target on shares of Evolent Health in a report on Friday, February 21st. Finally, Truist Financial lowered their price target on Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Evolent Health currently has an average rating of "Buy" and a consensus target price of $17.71.

Insider Activity at Evolent Health

In related news, Director Diane Holder purchased 2,735 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was acquired at an average price of $9.33 per share, for a total transaction of $25,517.55. Following the transaction, the director now directly owns 70,584 shares of the company's stock, valued at $658,548.72. This trade represents a 4.03 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Seth Blackley acquired 55,225 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the completion of the transaction, the chief executive officer now directly owns 762,217 shares of the company's stock, valued at $6,867,575.17. This represents a 7.81 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 74,000 shares of company stock worth $666,315 in the last quarter. 1.60% of the stock is owned by company insiders.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.